Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10…

📢 Get your spot now! MRI-based adaptive brachytherapy in gynae cancer 📍 29 Sept–2 Oct 2025 | Prague 🗓️ Early deadline: 2 July 💻 Pre-webinar: 4 Sept, 15:00 CEST ✨ Study in one of Europe’s most enchanting cities! 👉 bit.ly/40jV79R #Brachytherapy #GynaeOnc

Duration of Androgen Suppression with Postoperative Radiotherapy (DADS... sciencedirect.com/science/articl…

Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III Trial - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version) - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

Evaluation of brachytherapy applicators and their association with morbidity and local control in cervix cancer: An EMBRACE I analysis - Radiotherapy and Oncology thegreenjournal.com/article/S0167-…

ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025 - The Lancet Oncology thelancet.com/journals/lanoc…

BREAKING-ICE App© Informative Censoring Exploration timotheeolivier-research.com/breaking-ice

Recently published in The International Journal of Gynecologic Cancer ‼️ 🗞️ ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy. This provides an update to previous recommendations. Read the paper 👉 …l-journal-of-gynecological-cancer.com/article/S1048-… Learn

What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy? sciencedirect.com/science/articl…

Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer - European Urology Oncology euoncology.europeanurology.com/article/S2588-…

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial - The Lancet Oncology thelancet.com/journals/lanon…

#WRAD

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial - The Lancet Oncology thelancet.com/journals/lanon…

✨RadComp: First RCT of protons vs photons in breast #radiotherapy 🎀 At 6 mo, HRQOL (fatigue, body image, function) was excellent & similar in both arms ✅. 💨 FACIT - ⬆️satisfaction with protons 🚀 - not blinded though? #ASTRO25 #RadOnc ASTRO OncoAlert

📢 Phase III RCT in locally advanced #OPSCC: proton 💠 vs conventional #radiotherapy 🔆 ❌ No diff. in 12-mo gastrostomy rate, QOL, or swallowing. ⚖️ Similar 2-yr local control & OS (~95%). 👉 High-quality IMRT remains standard; IMPT not required. #ASTRO25 #RadOnc ASTRO

📢 NRGGU005 Phase III: 698 pts with intermediate-risk #ProstateCancer RCT; SBRT (n=353) vs M-IMRT (n=345) ✅ SBRT → better bowel HRQOL (MCID 35% vs 44%, p=0.03) ⚖️No diff in urinary HRQOL; EPIC continence favours SBRT ❌futile for DFS; IMRT had ⬇️3-yr biochemical failure (4.2%

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial - The Lancet Oncology thelancet.com/journals/lanon…